BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33405030)

  • 1. CRISPR-Cas9-Mediated Gene Silencing in Cultured Human Epithelia.
    Gago S; Overton NLD; Bowyer P
    Methods Mol Biol; 2021; 2260():37-47. PubMed ID: 33405030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells.
    Voets O; Tielen F; Elstak E; Benschop J; Grimbergen M; Stallen J; Janssen R; van Marle A; Essrich C
    PLoS One; 2017; 12(8):e0182974. PubMed ID: 28800587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optical Control of Genome Editing by Photoactivatable Cas9.
    Otabe T; Nihongaki Y; Sato M
    Methods Mol Biol; 2021; 2312():225-233. PubMed ID: 34228293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disabling Cas9 by an anti-CRISPR DNA mimic.
    Shin J; Jiang F; Liu JJ; Bray NL; Rauch BJ; Baik SH; Nogales E; Bondy-Denomy J; Corn JE; Doudna JA
    Sci Adv; 2017 Jul; 3(7):e1701620. PubMed ID: 28706995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
    Bai B; Myklebust JH; Wälchli S
    Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR: development of a technology and its applications.
    Derry WB
    FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR RNA-guided autonomous delivery of Cas9.
    Wilkinson RA; Martin C; Nemudryi AA; Wiedenheft B
    Nat Struct Mol Biol; 2019 Jan; 26(1):14-24. PubMed ID: 30598555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR Mediated Genome Engineering and its Application in Industry.
    Kaboli S; Babazada H
    Curr Issues Mol Biol; 2018; 26():81-92. PubMed ID: 28879858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-gRNA Design.
    Pallarès Masmitjà M; Knödlseder N; Güell M
    Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 genome editing technology in filamentous fungi: progress and perspective.
    Song R; Zhai Q; Sun L; Huang E; Zhang Y; Zhu Y; Guo Q; Tian Y; Zhao B; Lu H
    Appl Microbiol Biotechnol; 2019 Sep; 103(17):6919-6932. PubMed ID: 31332488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient genome editing by homology-directed repair using Cas9 protein in Ceratitis capitata.
    Aumann RA; Schetelig MF; Häcker I
    Insect Biochem Mol Biol; 2018 Oct; 101():85-93. PubMed ID: 30157456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.